Stocks can plunge for any number of reasons — investors may need to raise cash for large milestone purchases, or algorithms could be triggered by stop losses which create massive selloffs. Whatever the case, InvestorPlace’s journalists weed out the markets’ losers, keeping you informed of which stocks to cash out of before they come crashing down.
Stocks to Sell
Don’t Create Problems for Your Portfolio with Creatd
The poor performance of CRTD stock, along with a bleak fiscal picture for the company, add up to a highly unfavorable risk-to-reward profile.
Novavax Stock May Not Get the Delta Varient Bump Investors Need
While NVAX stock may enjoy increased relevance on paper due to the delta variant, investors should think about the bigger picture.
Weak Fundamentals Prove There Is No Reason to Buy Bionano Genomics
Bionano Genomics is risky and its valuation does not justify its price. There is no compelling argument for a buy in BNGO stock.
If You Bet on Workhorse, You’re Walking on Your Own
WKHS stock may have been a high-potential trade but without the USPS contract, it might meander aimlessly for a while.
Krispy Kreme Stock Should Drop 40% To $9.65 Before It Looks Reasonable
Krispy Kreme paid off a significant chunk of debt by going public, which we can use to calculate the actual value of DNUT stock.
Blackberry’s Time Has Passed. Stay Away From BB Stock.
The one-time giant of the tech world likes to say it is more than a meme stock, but its finances and outlook say otherwise. Avoid BB stock.
AMC Stock Faces a Day of Reckoning as Its Debt Load Multiplies
AMC has $11.05 billion in total debt. Could it pass a stress test? That’s an answer investors ought to get before buying AMC stock.
Ocugen Likely Can’t Get a Boost From the FDA Until 2023
It would likely take until mid-2023 for the FDA to approve Covaxin. By that time, the shot could be obsolete. Sell OCGN stock.
Clover Health Hasn’t Lived Up to Its Billing as a Healthcare Disruptor
CLOV stock has no competitive moat at this point, as its software has failed to garner traction among healthcare providers.
It’s Holding Up Now, But Gamestop Stock Could Still Tumble
GME stock has been resilient compared to other Reddit plays, but don't take that to mean it's immune from future declines.
Without a Solid Business Plan, GameStop Isn’t Worth It
GME stock might be down from its earlier highs, but don't think of this as a discount; the company doesn't have a bright future.
Fisker Stock Would Look a Whole Lot Better With Less Short Interest
FSR stock is trading at about 20% of its normal volume. This makes now a good time to reflect on whether Fisker will be disruptive or be disrupted.
Clover Health Is Either Cursed or Unlucky, but It’s Not a Buy Now
Is healthcare insurer Clover Health Investments more than a meme stock? This is the question that both professional and retail investors are trying to answer after CLOV stock was targeted in late May by the meme stock crowd that congregates on the WallStreetBets Reddit forum. Clover Health has to convince investors that it is more than a flash in the pan meme stock and that its shares are worthy of sustained gains.
GameStop Is Still Overvalued Despite More Positive Catalysts
Netflix's entrance into the vide-game sector could help GameStop, but the valuation of GME stock is still far too high.
Long-Term Investors Should Skip AMC Stock
AMC stock has certainly had an impressive several months, but a real recovery for AMC is unlikely due to streaming and Covid-19.
Mind Medicine Has More Obstacles Than Opportunities
MNMD stock could revolutionize mental healthcare with its novel therapeutics, but there are currently too many risks with its business.
